Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled colistimethate sodium once daily versus twice daily in cystic fibrosis with Pseudomonas aeruginosa infection
ACTRN12624000601538Phase 3Active, not recruiting
- Sponsor
- Spexis AG
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colistimethate sodium in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Spexis AG. Primary endpoint: Number of observed safety events during the 28-day treatment period in each treatment arm. Started Oct 2025; status: active, not recruiting.
02
Drugs
colistimethate sodium
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on ACTRN12624000601538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000601538.